Compare ELMD & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELMD | GALT |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.5M | 232.3M |
| IPO Year | 2010 | N/A |
| Metric | ELMD | GALT |
|---|---|---|
| Price | $28.02 | $5.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $36.00 | $6.00 |
| AVG Volume (30 Days) | 50.0K | ★ 390.3K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.89 | N/A |
| EPS | ★ 0.94 | N/A |
| Revenue | ★ $66,218,999.00 | N/A |
| Revenue This Year | $14.63 | N/A |
| Revenue Next Year | $11.54 | N/A |
| P/E Ratio | $29.53 | ★ N/A |
| Revenue Growth | ★ 16.05 | N/A |
| 52 Week Low | $17.73 | $0.73 |
| 52 Week High | $35.56 | $6.66 |
| Indicator | ELMD | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 63.93 | 53.34 |
| Support Level | $26.10 | $5.31 |
| Resistance Level | $27.94 | $5.88 |
| Average True Range (ATR) | 0.97 | 0.50 |
| MACD | 0.19 | -0.01 |
| Stochastic Oscillator | 83.77 | 38.46 |
Electromed Inc is a United States-based company that develops, manufactures, markets, and sells products that provide airway clearance therapy, including the SmartVest Airway Clearance System and related products, to patients with compromised pulmonary function with a commitment to excellence and compassionate service. The SmartVest System features a programmable air pulse generator, a therapy garment worn over the upper body and a connecting hose, which together provide safe, comfortable, and effective airway clearance therapy.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.